PRME - NASDAQ

Prime Medicine, Inc.

PRME·NASDAQ

$3.14

-2.2%

HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$567.14M

EPS-1.3500

P/E Ratio-2.33

Earnings Date08/06/2026

342.73M

Assets

15%

3Y-5.0%

5Y+526.0%

10Y+3841.0%

221.87M

Total Liabilities

54%

3Y+404.0%

5Y+941.0%

10Y+2936.0%

120.87M

Total Equity

-21%

3Y-62.0%

5Y+261.0%

10Y+8602.0%

Prime Medicine, Inc. Funding & Solvency Profile

PRME · NASDAQ

Current Assets

Cash & Cash Equivalents63.03M

Net Receivables0.00

Inventory0.00

Other Current Assets3.61M

Total Current Assets181 M

Non-Current Assets

Property, Plant & Equipment146.75M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets14.69M

Total Non-Current Assets161 M

Total Assets

342.73M

Financial Health Analysis

Current Ratio

4.84x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.84x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

144 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

53% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Prime Medicine, Inc. Balance Sheet

PRME • NASDAQ

Prime Medicine, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	63M	182.5M	41.6M	187.6M	185.4M	37M	8.6M
Short-Term Investments	114.6M	8M	80.1M	106.3M	84.2M	16.4M	0.0
Cash & Short-Term Investments	177.7M	190.4M	121.7M	293.9M	269.6M	53.3M	8.6M
Prepaids	0.0	6.8M	19.1M	2.5M	959K	74K	0.0
Other Current Assets	3.6M	14.7M	2.3M	246K	0.0	0.0	50K
Total Current Assets	181.3M	211.9M	143M	296.6M	270.6M	53.4M	8.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	146.7M	71.6M	36.6M	48.6M	15.7M	596K	0.0
Other Non-Current Assets	14.7M	14.1M	14.3M	15.1M	15.6M	785K	0.0
Total Non-Current Assets	161.4M	85.6M	50.9M	63.7M	31.3M	1.4M	0.0
Total Assets	342.7M	297.5M	193.9M	360.3M	301.9M	54.8M	8.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	8.9M	11.4M	19.5M	4.3M	1.4M	250K	0.0
Accounts Payable	8.9M	11.4M	19.5M	4.3M	1.4M	250K	0.0
Accrued Expenses	0.0	9M	16.7M	3.7M	34.5M	116K	0.0
Short Term Debt	8.1M	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	3.6M	9.3M	11.7M	7.3M	0.0	0.0
Deferred Revenue	7.8M	7.1M	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	12.6M	6.9M	10.9M	7M	14.7M	19.1M	7.3M
Total Current Liabilities	37.4M	38M	56.4M	26.7M	58M	19.4M	7.3M
NON-CURRENT LIABILITIES
Long Term Debt	108.3M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	63.2M	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	279K	1.2M	1.9M	0.0
Other Non-Current Liabilities	76.1M	6M	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	184.4M	106.4M	4.4M	17.3M	4.3M	1.9M	0.0
Capital Lease Obligations	0.0	40.8M	13.6M	28.7M	10.4M	0.0	0.0
Total Liabilities	221.9M	144.4M	60.8M	44M	62.3M	21.3M	7.3M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	395.8M	31.1M	4M
Common Stock	2K	2K	2K	2K	0.0	0.0	1K
Additional Paid-In Capital	0.0	840.4M	624.4M	609.8M	15.2M	8.3M	0.0
Retained Earnings	-888.4M	-687.2M	-491.3M	-293.2M	-171.4M	-6M	-2.6M
Accumulated Other Comprehensive Income/Loss	82K	1K	-15K	-384K	-27K	0.0	0.0
Other Total Stockholders' Equity	1B	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	120.9M	153.1M	133.1M	316.3M	239.6M	33.5M	1.4M
Total Equity	120.9M	153.1M	133.1M	316.3M	239.6M	33.5M	1.4M
SUMMARY
Total Liabilities & Equity	342.7M	297.5M	193.9M	360.3M	301.9M	54.8M	8.7M
Total Investments	114.6M	8M	80.1M	106.3M	84.2M	16.4M	0.0
Total Debt	116.4M	40.8M	13.6M	28.7M	10.4M	0.0	0.0
Net Debt	53.4M	-141.7M	-27.9M	-158.9M	-175M	-37M	-8.6M
Shares Outstanding	178,273,998	178,273,998	178,273,998	178,273,998	178,273,998	178,273,998	178,273,998

SEC Filings

PRME - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	April 23, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	April 16, 2026	April 07, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 03, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 03, 2026	March 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 07, 2025	November 07, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 07, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 08, 2025	September 08, 2025	2025	View Filing

Showing 1 to 10 of 65 filings

Related Guides

Blog Categories

Continue your PRME research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.